3-MeO-PCE
220px | |
Systematic (IUPAC) name | |
---|---|
N-ethyl-1-(3-methoxyphenyl)cyclohexanamine
|
|
Clinical data | |
Legal status |
|
Identifiers | |
CAS Number | 1364933-80-1 |
PubChem | CID: 57461569 |
ChemSpider | 27523972 |
Chemical data | |
Formula | C15H23NO |
Molecular mass | 233.36 g·mol−1 |
|
|
|
|
3-Methoxyeticyclidine (3-MeO-PCE) is a dissociative anesthetic drug that has been sold online as a designer drug.[1] The activity of 3-MeO-PCE in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCE was qualitatively similar to PCP.[2]
On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of Methoxetamine should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCE.[3]
This report also described the receptor binding profile of Methoxetamine and three additional dissociatives 3-MeO-PCP, 4-MeO-PCP and 3-MeO-PCE, showing them to have significant affinity for the PCP site of NMDAR and was later published in more detail.[4]
3-MeO-PCE has a Ki of 61 nM for the NMDA receptor, 115 nM for the serotonin transporter, 4519 nM for the sigma1 receptor and 525 nM for the sigma2 receptor.[4]
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
GABAA | |||||||||
---|---|---|---|---|---|---|---|---|---|
GABAB | |||||||||
H1 |
|
||||||||
α2-Adrenergic | |||||||||
5-HT2A |
|
||||||||
Melatonin | |||||||||
Orexin | |||||||||
Others | |||||||||
|
Receptor (ligands) |
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (blockers) |
|
||||||||||||||||||||||
Enzyme (inhibitors) |
|
||||||||||||||||||||||
Others | |||||||||||||||||||||||
Receptor |
|
---|
<templatestyles src="Asbox/styles.css"></templatestyles>
![]() |
This Hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |
- Pages with reference errors
- Pages with broken file links
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Articles containing unverified chemical infoboxes
- Dissociative drugs
- O-Methylated phenols
- Designer drugs
- Hallucinogen stubs